title: Management of von Willebrand disease type 3 during pregnancy - 2 cases reports.
abstract: BACKGROUND
  von Willebrand disease type 3, is an extremely rare condition. It can be severe and potentially life-threatening, particularly in pregnant women during labor and subsequently during early puerperium. Due to its rarity, there is no optimal treatment/management during pregnancy.
  
  
  METHODS
  We describe two cases of pregnant women with von Willebrand disease type 3, and its successful surveillance and treatment with Haemate P FVIII (human plasma-derived von Willebrand Factor-ristocetin co-factor associated with human coagulation factor VIII), during pregnancy, partum and puerperium.
  
  
  CONCLUSIONS
  Daily prophylaxis with Haemate P FVIII in women with von Willebrand disease type 3, starting 2 hours before caesarean section until the 7th day of puerperium, associated with close analytical and clinical surveillance seems to be a safe clinical option.
authors.affiliation: Maternidade Júlio Dinis, Centro Hospitalar do Porto, Porto, Portugal. dr.inocencio@gmail.com  
authors.forename: G
authors.initials: G
authors.lastname: Inocêncio
authors.forename: A
authors.initials: A
authors.lastname: Braga
authors.forename: S
authors.initials: S
authors.lastname: Azevedo
authors.forename: G
authors.initials: G
authors.lastname: Buchner
mesh_terms: D000328:Adult; D004338:Drug Combinations; D005169:Factor VIII / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D049590:Postpartum Period; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000503:physiopathology / Q000628:therapy*; D011256:Pregnancy Outcome; D016896:Treatment Outcome; D014842:von Willebrand Diseases / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D014841:von Willebrand Factor / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; C509423:factor VIII, von Willebrand factor drug combination; D014841:von Willebrand Factor; D005169:Factor VIII